达格列净对DAPA-HF研究中室性心律失常、复苏后心脏骤停或心源性猝死的影响
该研究为DAPA-HF试验的事后分析,纳入4744例射血分数降低的心力衰竭(HFrEF)患者,评估达格列净对比安慰剂对严重室性心律失常、复苏后心脏骤停或心源性猝死复合终点的影响。结果显示达格列净组复合终点发生率为5.9%,安慰剂组为7.4%(HR 0.79,95%CI 0.63-0.99,P=0.037),且各组分效应一致。
要点
- 达格列净降低HFrEF患者严重室性心律失常、心脏骤停或心源性猝死复合风险(HR 0.79)。
- 复合终点各组分(室性心律失常、复苏后心脏骤停、心源性猝死)效应一致。
- 严重室性心律失常总体报告率为2.4%(115/4744例)。
核心结论
- 在常规治疗基础上加用达格列净可降低HFrEF患者严重室性心律失常、心脏骤停或心源性猝死的风险。
研究设计与样本
- DAPA-HF试验的事后分析,共纳入4744例HFrEF患者,比较达格列净与安慰剂。
- 复合终点为首次发生任何严重室性心律失常、复苏后心脏骤停或心源性猝死的组合,采用Cox比例风险模型分析。
主要发现
- 4744例患者中115例(2.4%)报告严重室性心律失常:心室颤动15例、室性心动过速86例、其他室性心律失常/快速性心律失常12例、尖端扭转型室速2例。
- 500例心血管死亡中206例(41%)为猝死;8例患者心脏骤停复苏后存活。
- 达格列净组140/2373例(5.9%)发生复合终点,安慰剂组175/2371例(7.4%),HR 0.79(95%CI 0.63-0.99),P=0.037。
- 复合终点各组分效应一致。
- 复合终点的独立预测因素(按卡方值排序)包括:对数转换的N末端B型利钠肽原、室性心律失常病史、左心室射血分数、收缩压、心肌梗死病史、男性、体重指数、血清钠浓度、非白人种族、达格列净治疗和心脏再同步化治疗。
临床怎么用
- 对于HFrEF患者,在常规治疗基础上加用达格列净可能有助于降低严重室性心律失常、心脏骤停或心源性猝死的风险。
局限性
- 本研究为DAPA-HF试验的事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aim of this study was to examine the effect of dapagliflozin on the incidence of ventricular arrhythmias and sudden death in patients with heart failure and reduced ejection fraction (HFrEF). METHODS AND RESULTS: In a post hoc analysis of DAPA-HF, we examined serious adverse event reports related to ventricular arrhythmias or cardiac arrest, in addition to adjudicated sudden death. The effect of dapagliflozin, compared with placebo, on the composite of the first occurrence of any serious ventricular arrhythmia, resuscitated cardiac arrest, or sudden death was examined using Cox proportional hazards models. A serious ventricular arrhythmia was reported in 115 (2.4%) of the 4744 patients in DAPA-HF (ventricular fibrillation in 15 patients, ventricular tachycardia in 86, 'other' ventricular arrhythmia/tachyarrhythmia in 12, and torsade de pointes in 2 patients). A total of 206 (41%) of the 500 cardiovascular deaths occurred suddenly. Eight patients survived resuscitation from cardiac arrest. Independent predictors of the composite outcome (first occurrence of any serious ventricular arrhythmia, resuscitated cardiac arrest or sudden death), ranked by chi-square value, were log-transformed N-terminal pro-B-type natriuretic peptide, history of ventricular arrhythmia, left ventricular ejection fraction, systolic blood pressure, history of myocardial infarction, male sex, body mass index, serum sodium concentration, non-white race, treatment with dapagliflozin, and cardiac resynchronization therapy. Of participants assigned to dapagliflozin, 140/2373 patients (5.9%) experienced the composite outcome compared with 175/2371 patients (7.4%) in the placebo group [hazard ratio 0.79 (95% confidence interval 0.63-0.99), P = 0.037], and the effect was consistent across each of the components of the composite outcome. CONCLUSIONS: Dapagliflozin reduced the risk of any serious ventricular arrhythmia, cardiac arrest, or sudden death when added to conventional therapy in patients with HFrEF. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov unique identifier: NCT03036124 (DAPA-HF).
引用
- Curtain JP, Docherty KF, Jhund PS, et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J. 2021. PMID: 34448003. doi:10.1093/eurheartj/ehab560
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。